Studying estrogen receptor status in breast cancer, Gruvberger and collaborators also demonstrated that a high level of SELENBP1 expression was present in ER+ tumors but not ER– ones (Fig. 1 and Table 3 in [36]). Here, SELENBP1 is linked to breast cancer.